直接口服抗凝药在病态肥胖患者中的应用
本综述分析了MEDLINE等数据库截至2019年的19项研究,评估病态肥胖合并房颤或静脉血栓栓塞患者使用直接口服抗凝药(DOACs)的情况。现有数据未显示DOACs在该人群中有问题,但存在DOAC特异性药代动力学变异,且VTE治疗数据少于房颤卒中预防。研究质量偏低,建议继续谨慎使用,尤其VTE治疗。
要点
- 现有数据未显示病态肥胖患者使用DOACs存在问题,但存在药代动力学变异。
- VTE治疗中DOACs的疗效与安全性数据少于房颤卒中预防。
- 研究质量低,建议继续谨慎使用DOACs,尤其VTE治疗。
核心结论
- 现有数据未表明病态肥胖患者使用DOACs存在问题,但观察到DOAC特异性药代动力学变异。
- VTE治疗中DOACs的疗效与安全性数据少于房颤患者卒中预防的数据。
- 研究整体质量低,建议在病态肥胖患者中继续谨慎使用DOACs,尤其VTE治疗,直至更高质量数据出现。
研究设计与样本
- 综述分析了MEDLINE数据库(从建库至2019年5月29日)、Cochrane Library、Google Scholar和EMBASE数据库(从建库至2019年4月26日)的文献。
- 共纳入19项研究,包括药代动力学研究、DOACs的原始III期试验、III期试验的事后分析和回顾性队列研究。
主要发现
- 现有数据未显示病态肥胖患者使用DOACs存在问题。
- 观察到DOAC特异性药代动力学变异。
- VTE治疗中DOACs的疗效与安全性数据少于房颤卒中预防的数据。
临床怎么用
- 在病态肥胖患者中考虑使用DOACs时应继续谨慎,尤其对于需要抗凝治疗VTE的患者。
局限性
- 纳入研究整体质量低,因缺乏前瞻性随机试验数据,限制了对病态肥胖患者中DOACs疗效和安全性的明确判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with morbid obesity due to limited clinical efficacy and safety data supporting their use in this patient population. In this review, we analyzed published articles in the MEDLINE database (from inception through May 29, 2019), and the Cochrane Library, Google Scholar, and EMBASE databases (from inception through April 26, 2019) that evaluated morbidly obese patients with atrial fibrillation (AF) or venous thromboembolism (VTE) who received DOACs. A total of 19 studies, which included pharmacokinetic studies, original phase III trials for the DOACs, post hoc analyses of phase III trials, and retrospective cohort studies, were evaluated. Although currently available data do not indicate that using DOACs in the morbidly obese is problematic, DOAC-specific pharmacokinetic variations have been observed. Additionally, less data evaluating DOAC efficacy and safety exist for VTE treatment compared with the data for stroke prevention in patients with AF. The overall quality of the studies included in this review was low due to limited prospective randomized trial data, limiting the ability to form definitive judgments on efficacy and safety DOACs in the morbidly obese. Continued caution is recommended when considering DOAC use in the morbidly obese, particularly for those requiring anticoagulation for VTE treatment, until additional higher-quality data become available.
引用
- Kido K, Lee JC, Hellwig T, et al. Use of Direct Oral Anticoagulants in Morbidly Obese Patients. Pharmacotherapy. 2019. PMID: 31834939. doi:10.1002/phar.2353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。